Search
Nadide
go.drugbank.com/drugs/DB14128InvestigationalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Pegsunercept
go.drugbank.com/drugs/DB06611InvestigationalPhase II clinical trials were completed in January 2010.
Categories: Compounds used in a research, industrial, or household settingNetilmicin
go.drugbank.com/drugs/DB00955ApprovedNetilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site.
Synonyms: 1-N-EthylsisomicinCIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalThe vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.
Culex pipiens
go.drugbank.com/drugs/DB14165ApprovedCulex pipiens allergenic extract is used in allergenic testing.
Sarocladium strictum
go.drugbank.com/drugs/DB14168ApprovedSarocladium strictum allergenic extract is used in allergenic testing.
GW 468816
go.drugbank.com/drugs/DB05417InvestigationalIt is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.
Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitorsOSU-6162
go.drugbank.com/drugs/DB19178InvestigationalOSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalAs of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). … Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein.